drugset / Trial / NCT00234533

Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq

NCT00234533

Phase 3 Completed 251 enrolled Ipsen
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.

Timeline

Start
2004-06
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 0.025 mg/kg Subcutaneous
Subject Somatropin Protein / enzyme biologic 0.035 mg/kg Subcutaneous
Subject Somatropin Protein / enzyme biologic 0.05 mg/kg Subcutaneous